Advertisement

Topics

Marinus Claims Phase 2 Postpartum Depression Win, Analysts Less Sure

13:31 EST 10 Dec 2018 | Xconomy

Marinus Pharmaceuticals says its treatment for postpartum depression (PPD) is showing encouraging results in a mid-stage study—enough to continue clinical development. But it’s unclear whether the results are statistically significant or enough to make the drug competitive against a Sage Therapeutics drug now awaiting an FDA decision for the same condition. Marinus (NASDAQ: MRNS) said […]

Original Article: Marinus Claims Phase 2 Postpartum Depression Win, Analysts Less Sure

NEXT ARTICLE

More From BioPortfolio on "Marinus Claims Phase 2 Postpartum Depression Win, Analysts Less Sure"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mental Health
Adhd Anorexia Depression Dyslexia Mental Health Psychiatry Schizophrenia Stress Mental health, although not being as obvious as physical health, is very important, causing great unhappiness to those affected, causing add...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...